This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The move follows the 2019 merger between Caprion and HistoGeneX , a Belgian histopathology and genomics lab. We wanted to create a brand that is unique in the market, relevant to our clients and inspiring to our employees around the world,” said Nick Wright, president and COO of CellCarta, in a statement about the rebrand. “Our
Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. The CancerSEEK blood test is designed to detect multiple cancers by analysing tumour specific genomic mutations in circulating tumor DNA (ctDNA) and cancer-associated protein biomarkers in plasma.
The team has focused initially on non-small cell lung cancer (NSCLC), the most common form of lung cancer, but say the same principles could be applied to other tumour types, and combined with other testing approaches like genomics to inform treatment decisions.
Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves 1. Concentrating on patient identification early in the clinical phases can drive brand loyalty and develop more effective tactics, to address unmet patient needs.
As more patients turn to digital platforms for information and brands compete in an increasingly crowded market, pharma marketers need to be agile, creative, and tech-savvy to succeed. Personalized medicine, often driven by genomic data, is revolutionizing how treatments are marketed. How do you keep up?
Exact Sciences’ Precision Oncology portfolio provides actionable genomic insights to detect cancer earlier and provides guidance for successful treatment following a diagnosis. Exact Sciences is also investing in its pipeline to develop innovative solutions before, during and after a cancer diagnosis.
Berlin, March 23, 2021 – Bayer announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for larotrectinib, under the brand name Vitrakvi , for the treatment of Neurotrophic Tyrosine Receptor Kinase ( NTRK ) fusion-positive advanced or recurrent solid tumors. Fields, M.D.,
With advancements in genomics and biotechnology, there is a move towards tailoring treatments to individual patients based on their genetic makeup. Pharma executives must navigate these regulatory complexities while maintaining compliance to protect their brand reputation and foster trust with stakeholders.
The San Nicolás site supports Bayer’s global vegetable seeds R&D pipeline for varieties sold to customers in more than 130 countries and territories under the Seminis ® and De Ruiter ® brands, both united under Vegetables by Bayer. “By The Bayer brand stands for trust, reliability and quality throughout the world. billion euros.
Israel and Taiwan under the brand name Aliqopa. o Abstract CT020; April 10, 2:50pm EDT. • Prognosis and molecular characteristics of patients with TRK fusion cancer in the 100,000 Genomes Project. Copanlisib, the only pan class I phosphatidylinositol-3-kinase (PI3K) inhibitor given intravenously, is currently approved in the U.S.,
We will make full use of our advantages, such as nationwide marketing, promotion, networking, to formulate market strategies, complete academic promotion, brand management and other integrated services together with CHIPCREEN BIOSCIENCES. ” About CHIPSCREEN BIOSCIENCES. Chipscreen Biosciences, Stock Symbol: 688321.SH)
These data reinforce the importance of early comprehensive genomic testing to uncover actionable oncogenic drivers, including NTRK gene fusions, to assist identify patients who are presumably to profit from a targeted treatment approach.”. The Bayer brand stands for trust, reliability and quality throughout the world. billion euros.
By leveraging data from genomic studies and electronic health records, marketers can identify niche markets and craft messages that speak directly to the needs and concerns of specific patient populations. Influencers can effectively demystify complex medical information, making it more accessible and relatable to the general public.
Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., These are critical, both for educational reasons (they can be effective in bringing abstract or complex concepts to life) and promotional purposes (to create a distinct brand identity in the crowded landscape).
The Bayer brand stands for trust, reliability and quality throughout the world. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. billion euros. billion euros.
By fostering a sense of community, addressing pain points and sharing impactful stories, podcasts can strengthen ties with an audience, drive brand loyalty and help life science organizations position themselves for long-term success in an increasingly competitive landscape. Have questions?
There will be a brand-new treatment for actinic keratosis on the market next year, with Tuesday’s FDA approval of Athenix’s Klisyri® (tirbanibulin). This will be the first branded proprietary product for Athenex, which will be launched in the U.S. at the time of the announcement. Athenex, Inc. When Pigs Fly Allergy-friendly.
The approach combines phenotypic screening, proteomics, and genomics-based technologies with machine learning-powered analysis of data, avoiding the use of standard growth inhibition assays which can be slow and may miss potentially promising mechanisms. million deaths a year, according to the 2019 Gram Report.
For marketing executives, understanding the significance of leading pharma brands is essential. These brands don’t just sell medications; they cultivate trust, manage reputations, and create value through their strategies. This article explores the leaders in the sector and the trends shaping their future.
FDA for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Prioritized Brands. . . . . . . . . . . . Established Brands. . . . . . . . . . . . Other Brands (a). Worldwide Revenues. . Revlimid. $.
Marieke Oudelaar (Max Planck Institute for Biophysical Chemistry in Göttingen) for her outstanding contributions in the development of methods to characterize the 3D structure of the genome and her work on the interaction between gene-regulatory elements at specific gene loci. Dr. Connor W. billion euros. billion euros.
Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. Now, researchers reporting in ACS Central Science have identified small molecules that target a structure within the RNA genome […].
The name Zeneca was invented by a branding consultancy who had been instructed to find a name which was memorable, had no associations with other companies, nor was offensive in any language”. The profits from these products funded the development of new drugs, such as gastroesophageal treatment Losec and cardiovascular treatment Aptin.
“Our novel AI technology produces a brand new dataset that accurately represents all of the statistical patterns in the underlying health records. With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D.
About Syntegra.
Surufatinib will be marketed in China under the brand name Sulanda. Eurofins Genomics – Luxemburg-based Eurofins Genomics launched an optimized next-generation sequencing service providing full length viral genome sequences for COVID-19. Top line data are expected in late January or early February 2021.
Parker Moss, chief ecosystems and partnership officer at Genomics England, spoke from the audience, mentioning how it is harder to get reimbursement for a diagnostics marker. Reimbursement and diagnostics markers. He asked what should be done in an increasingly stratified world.
(NYSE: TMO) today announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.
million (DKK 585 million) to the Ancient Environmental Genomics Initiative for Sustainability (AEGIS), advancing climate-resilient crops and showcasing its broader commitment to global sustainability. Though the companys sustainable revenue accounts for just 4%, Novo Nordisk actively invests in broader environmental initiatives.
New variant-hardy AbCellera-Lilly mAb shows utility of viral genomics surveillance ( BioCentury ).
AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ).
The weird science of the placebo effect keeps getting more interesting ( Vox ).
Pfizer’s TBE vaccine, marketed under the brand names TicoVac and FSME-Immun in Europe, is an inactivated whole virus vaccine developed using a master ‘seed’ virus that is similar to the TBE virus found in nature. Complete Genome Sequences of Four European Subtype Strains of Tick-Borne Encephalitis Virus from Eastern Siberia, Russia.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content